Melillo L, Musto P, Tomasi P, Cascavilla N, Bodenizza C, Ladogana S, Carotenuto M
Divisione di Ematologia, Ospedale Generale Regionale Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Foggia.
Tumori. 1988 Apr 30;74(2):129-35. doi: 10.1177/030089168807400202.
Beta 2-microglobulin (B2m) was measured on serum samples in 274 patients with acute and chronic lymphoproliferative disorders (85 non-Hodgkin lymphomas-NHL, 30 Hodgkin lymphomas-HL, 34 B-cell chronic lymphocytic leukemias-B-CLL, 8 Waldenström macroglobulinemias-WM, 76 multiple myelomas-MM, 31 acute lymphoblastic leukemias-ALL, 10 hairy cell leukemias-HCL). Two hundred and four patients were studied at the time of diagnosis, and results were correlated to clinical stage, and histologic subtype in NHL, immunoglobulin type in MM, and immunologic phenotype in ALL. Moreover, B2m was tested during and after chemo- and/or radiotherapy, and results were correlated to response, progression or relapse. Elevated pretreatment B2m values were found in widespread forms of NHL and HL, in patients with B symptoms and in the unfavorable histologic subgroups of NHL. Rapid falls in levels followed therapy institution. In B-CLL and in MM a close relationship between B2m and cell mass was found. A significant B2m level reduction followed treatment, whereas its increase could detect a relapse. In ALL, serum B2m was only slightly above the normal range. B2m seems to reflect the total burden of malignant cells mainly in MM and B-CLL; in other lymphoproliferative disorders it provides less prognostic information.
对274例急慢性淋巴细胞增殖性疾病患者的血清样本进行了β2微球蛋白（B2m）检测（85例非霍奇金淋巴瘤-NHL、30例霍奇金淋巴瘤-HL、34例B细胞慢性淋巴细胞白血病-B-CLL、8例华氏巨球蛋白血症-WM、76例多发性骨髓瘤-MM、31例急性淋巴细胞白血病-ALL、10例毛细胞白血病-HCL）。204例患者在诊断时进行了研究，结果与临床分期、NHL的组织学亚型、MM的免疫球蛋白类型以及ALL的免疫表型相关。此外，在化疗和/或放疗期间及之后检测了B2m，结果与反应、进展或复发相关。在广泛型NHL和HL、有B症状的患者以及NHL的不良组织学亚组中发现预处理时B2m值升高。治疗开始后水平迅速下降。在B-CLL和MM中发现B2m与细胞量密切相关。治疗后B2m水平显著降低，而其升高可检测到复发。在ALL中，血清B2m仅略高于正常范围。B2m似乎主要在MM和B-CLL中反映恶性细胞的总负荷；在其他淋巴细胞增殖性疾病中，它提供的预后信息较少。
